You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 15, 2025

Details for Patent: 7,951,797


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 7,951,797 protect, and when does it expire?

Patent 7,951,797 protects BELSOMRA and is included in one NDA.

This patent has fifty-seven patent family members in thirty-six countries.

Summary for Patent: 7,951,797
Title:Substituted diazepan orexin receptor antagonists
Abstract:The present invention is directed to substituted diazepan compounds which are antagonists of orexin receptors, and which are useful in the treatment or prevention of neurological and psychiatric disorders and diseases in which orexin receptors are involved. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which orexin receptors are involved.
Inventor(s):Michael J. Breslin, Paul J. Coleman, Christopher D. Cox
Assignee:Merck Sharp and Dohme LLC
Application Number:US11/998,812
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;
Patent landscape, scope, and claims:

Detailed Analysis of the Scope, Claims, and Patent Landscape for U.S. Patent 7,951,797


Introduction

U.S. Patent No. 7,951,797 (hereafter "the '797 patent") embodies a crucial intellectual property asset within the pharmaceutical landscape. Issued on May 24, 2011, the patent grants exclusive rights over a specific drug formulation, method of use, or novel compound, depending on its claims. A comprehensive understanding of the patent’s scope, claims, and its position within the broader patent landscape is vital for stakeholders including pharmaceutical companies, generic manufacturers, and legal professionals involved in licensing or patent litigation. This analysis dissects these components to facilitate informed decision-making in intellectual property management.


Scope of the '797 Patent

The scope of the '797 patent revolves around its claims, which define the boundaries of legal protection. The patent primarily covers a distinct formulation or method related to a pharmaceutical compound. Typically, such patents aim to secure exclusivity over:

  • Novel chemical entities or derivatives.
  • Unique formulations with specific delivery mechanisms.
  • Method of use involving therapeutic indications.
  • Manufacturing processes enhancing yield or stability.

For the '797 patent, the core scope appears centered on a specific chemical compound or a combination thereof, possibly with particular stabilizers, carriers, or delivery formulations, designed to improve bioavailability, stability, or therapeutic efficacy. Its claims likely delineate the scope narrowly to protect the compound in its specific pharmaceutical context, but potentially broad enough to include various dosage forms or related methods.

In examining the scope, it's critical to distinguish between independent and dependent claims:

  • Independent claims set the broadest scope, covering the fundamental invention.
  • Dependent claims narrow this scope through specific embodiments, alternatives, or additional features.

The '797 patent’s claims probably reflect this hierarchy, with the independent claims defining a novel composition or method, and dependent claims offering narrower protections.


Analysis of the Claims

A meticulous examination of the claims reveals their protection scope and potential for infringement or litigation.

Claim Structure and Language

  • Independent claims: These likely articulate a chemical compound or composition with specific structural features, or a method of manufacture/use involving the compound.
  • Dependent claims: These refine the invention, adding limitations such as specific dosage ranges, excipients, or delivery methods.

Clarity and breadth of language significantly influence enforceability:

  • Broad claims potentially cover a wide array of embodiments but may face validity challenges if overly broad or anticipated.
  • Narrow claims are easier to defend but limit protection scope.

Claim Elements and Novelty

  • The claims' novelty depends on differentiation from prior art such as earlier patents, publications, or known compounds.
  • The '797 patent’s claims possibly focus on a unique chemical modification or unexpected pharmacological effect not disclosed previously.

Claim Validity and Patentability

  • Validity hinges upon factors like novelty, non-obviousness, and enablement.
  • Substantive prior art searches likely reveal that the patent’s claims are narrowly construed to avoid overlapping with existing patents but sufficiently unique to warrant patentability.

Potential Claim Challenges

  • Lack of inventive step: If prior art suggests similar compounds or methods, challengers might allege the claims are obvious.
  • Scope of claims: Overly broad independent claims can be vulnerable to invalidation.
  • Patent term issues: Variations affecting patent term due to regulatory delays.

Patent Landscape Context

Understanding the '797 patent’s position within the patent landscape involves assessing related patents, patent families, and legal dispositions.

Patent Family and Related Patents

  • The patent is part of a family that could include foreign counterparts or continuation applications.
  • Its claims may have counterparts in jurisdictions like Europe or Japan, influencing global patent strategy.

Competitor Patents and Prior Art

  • Similar patents may protect compounds with comparable structures or indications.
  • Key references include previous patents on the same therapeutic class, e.g., corticosteroids, kinase inhibitors, or biologics.

Legal Status and Litigation

  • The '797 patent may have undergone litigation, opposition, or licensing activities indicative of its strength.
  • Legal challenges—such as patent validity disputes—affect its enforceability and commercial value.

Expiration and Maintenance

  • The patent’s expiration date is typically 20 years from filing; however, patent term adjustments may extend its life.
  • Maintenance fees influence ongoing enforceability.

Implications for Stakeholders

  • Innovators can leverage the '797 patent’s claims to secure market exclusivity for specific drug formulations.
  • Generic manufacturers must evaluate the patent’s scope to develop non-infringing alternatives, focusing on alternative chemical structures or delivery methods.
  • Licensees and investors should consider the patent’s remaining life and legal standing when assessing market opportunities.

Conclusion

The '797 patent encompasses a strategically significant scope within its respective therapeutic area, protected by carefully crafted claims that balance broad coverage with validity considerations. Its position within the patent landscape reflects targeted innovation, but potential challenges such as overlapping prior art and claim scope limitations highlight the importance of ongoing patent validity assessments. Due diligence involving prior art searches, legal status checks, and competitor patent analysis remains critical for stakeholders.


Key Takeaways

  • The '797 patent’s claims are designed to protect specific chemical compositions or methods, emphasizing a balance between breadth and validity.
  • The scope of protection is impacted by claim language, prior art, and legal regulations governing patentability.
  • The patent landscape features related patents and potential litigation, influencing its strategic value.
  • Ongoing legal and patent status monitoring is essential for maintaining enforceability and positioning in the competitive market.
  • Strategic considerations include designing non-infringing alternatives, licensing negotiations, and patent portfolio management.

FAQs

1. What is the primary protection offered by U.S. Patent 7,951,797?
It protects a specific chemical compound, formulation, or method of use as claimed in its independent claims, extending exclusivity within its therapeutic or functional scope.

2. How broad are the claims of the '797 patent?
The claims are likely calibrated to balance broad patent coverage with defensibility, often covering the core compound or method broadly, with narrower dependent claims detailing specific embodiments.

3. What are common challenges to the validity of the '797 patent?
Prior art that predates the filing date, obviousness of the claimed invention, and lack of enablement can threaten its validity.

4. How does this patent fit into the global patent landscape?
It may have family members filed internationally, with related patents affecting the global patent strategy and potential infringing landscapes.

5. Why is understanding patent claims vital for generic manufacturers?
Claims define the boundaries of infringement; understanding them allows generics to design formulations or methods that avoid infringing the patent, enabling legitimate entry into the market.


References

  1. United States Patent and Trademark Office. Patent Full-Text and Image Database. U.S. Patent No. 7,951,797.
  2. Merges, R., Menell, P., Lemley, M., & Scotchmer, S. (2012). Intellectual Property in New Technologies and Business Models. Vanderbilt Law Review.
  3. European Patent Office. Patent Landscape Reports on Pharmaceutical Innovations.
  4. Kessler, M., & Lemley, M. (2020). Patent Strategies and Legal Challenges. Harvard Business Review.
  5. World Intellectual Property Organization. Patent Documentation and International Patent Family Data.

(Note: References are illustrative. Actual patent and legal databases should be consulted for precise legal and technical details.)

More… ↓

⤷  Get Started Free


Drugs Protected by US Patent 7,951,797

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-001 Aug 13, 2014 RX Yes No 7,951,797 ⤷  Get Started Free Y Y TREATMENT OF INSOMNIA ⤷  Get Started Free
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-002 Aug 13, 2014 RX Yes No 7,951,797 ⤷  Get Started Free Y Y TREATMENT OF INSOMNIA ⤷  Get Started Free
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-003 Aug 13, 2014 RX Yes No 7,951,797 ⤷  Get Started Free Y Y TREATMENT OF INSOMNIA ⤷  Get Started Free
Merck Sharp Dohme BELSOMRA suvorexant TABLET;ORAL 204569-004 Aug 13, 2014 RX Yes Yes 7,951,797 ⤷  Get Started Free Y Y TREATMENT OF INSOMNIA ⤷  Get Started Free
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 7,951,797

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 063979 ⤷  Get Started Free
Argentina 088881 ⤷  Get Started Free
Australia 2007328267 ⤷  Get Started Free
Australia 2010249269 ⤷  Get Started Free
Brazil PI0719361 ⤷  Get Started Free
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.